Answers are grounded in this paper and cite their sources.
People with multiple sclerosis (pwMS) have an increased risk of infections. There are limited data characterizing who initially diagnoses infections in pwMS and how these are communicated among healthcare providers. Retrospective US claims data from January 1, 2017 to August 31, 2024 were used to identify newly diagnosed pwMS aged 18–64 years who were taking any disease-modifying therapy (DMT) for ≥ 90 days. Index date was the earliest date of the first DMT claim. Infections were based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Severe infections included events requiring hospitalization and/or intravenous antibiotics. Overall, 69,148 pwMS who were treatment-naïve met eligibility criteria. Mean age was 44.1 years; 72% were female; and 81% were < 1 year from initial MS diagnosis to DMT initiation. A total of 316,497 infection events were reported over the study period, with 98% first reported by non-neurology providers. There were 21,416 severe infection events reported, of which > 98% were first reported by non-neurologists. In pwMS with infection events first reported by non-neurologists, 6% had a neurology visit ≤ 7 days after initial infection; of those, 8% had any infection ICD-10-CM code recorded at that visit (increased to 19% for serious infections). In the 16% of pwMS with a neurology visit ≤ 30 days post initial infection reported by a non-neurologist, 6% had any infection ICD-10-CM code recorded at that neurology visit (increased to 14% for severe infections). Most infections in pwMS are first reported by non-neurology providers, as most pwMS did not interact with their MS clinician in the first few months after infection, even if that infection was severe. These data highlight the importance of communication between different providers and patients to accurately assess patient status and DMT safety, leading to improved patient outcomes. Multiple sclerosis (MS) is a chronic neuroinflammatory disease with a wide range of symptom manifestations related to neurodegeneration within the brain and spinal cord. Infections, the most frequent coexisting condition in people with MS (pwMS), are associated with advanced MS-related disability and treatment with certain disease-modifying therapies (DMTs). As infections are typically diagnosed by non-neurologists, it is unclear if and how soon after an infection a pwMS has a visit with a neurologist. This study, using data from the Komodo Health claims database (from January 1, 2017 through August 31, 2024), was undertaken to determine which healthcare providers initially diagnose infection and which infections are commonly diagnosed in pwMS; the proportion of subsequent neurology visits after infection; and the likelihood of infections being recorded at that neurology visit. A total of 316,497 infections were reported over the study period, in which > 98% were first reported by non-neurology providers. Urinary tract infection (UTI) and coronavirus disease 2019 (COVID-19) were the two most common infections reported by non-neurologists and neurologists (UTI: 21.3% and 31.3%, respectively; COVID-19: 8.2% and 11.5%, respectively). In pwMS with infection events first reported by non-neurologists, 16% of pwMS had a neurology visit ≤ 30 days after initial infection diagnosis. Because most infections in pwMS are first reported by primary care providers, communication between non-neurology providers, MS specialists, and patients is key for an accurate assessment of DMT-related safety.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: